Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 16,142 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorders Clear all
Completed Not applicable Interventional Results available

CellFX System for the Treatment of Cutaneous Non-Genital Warts

NCT04554394
View directory record Official record
Conditions
Warts, Warts Hand, Verruca
Interventions
CellFX Device
Device
Lead sponsor
Pulse Biosciences, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Scottsdale, Arizona • San Diego, California • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Nov 11, 2026, 5:49 AM EST
Recruiting No phase listed Observational

The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise

NCT01011712
View directory record Official record
Conditions
EBV, HSV, VZV, HPV, CMV
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 100 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 11, 2026, 5:49 AM EST
Completed Phase 3 Interventional Results available

Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses

NCT01143181
View directory record Official record
Conditions
Double-stranded DNA Virus
Interventions
Brincidofovir
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
37
States / cities
Loma Linda, California • Los Angeles, California • Orange, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Nov 11, 2026, 5:49 AM EST
Completed No phase listed Observational

The Acquisition of Blood and Skin Samples From Normal Volunteers to Support Research Activities on Dermatologic Diseases

NCT00001505
View directory record Official record
Conditions
Healthy Volunteer, Dermatologic Diseases, Systemic Diseases
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 11, 2026, 5:49 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers

Clinical Study to Evaluate the Efficacy and Safety of Two Marketed Investigational Products in Children With Diaper Rash

NCT00219466
View directory record Official record
Conditions
Diaper Rash
Interventions
Zinc Oxide Diaper Rash Ointment, Aloe Vera/Tocopherol/Zinc Oxide Cream
Other
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
2 Months to 36 Months
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2011 · Synced Nov 11, 2026, 5:49 AM EST
Terminated Phase 1Phase 2 Interventional Results available

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

NCT03992131
View directory record Official record
Conditions
Ovarian Cancer, Triple-negative Breast Cancer, Urothelial Carcinoma, Solid Tumor
Interventions
Rucaparib, Lucitanib, Sacituzumab govitecan
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Boston, Massachusetts • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Nov 11, 2026, 5:49 AM EST
Completed Phase 2 Interventional Results available

Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery

NCT00450372
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
ADI-PEG-20, Pharmacology Studies
Biological · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Nov 11, 2026, 5:49 AM EST
Completed Phase 1 Interventional Results available

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

NCT02586675
View directory record Official record
Conditions
Breast Cancer, Breast Cancer - Female, Breast Cancer - Male
Interventions
Tamoxifen, Ribociclib, Goserelin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Nov 11, 2026, 5:49 AM EST
Not listed No phase listed Observational

Lupus Interval Monitoring to Manage Disease Flare and Enable Treatment Optimization

NCT03142412
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus, Lupus Erythematosus, Lupus Erythematosus, Systemic
Interventions
Not listed
Lead sponsor
DxTerity Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Compton, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Nov 11, 2026, 5:49 AM EST
Terminated Phase 2 Interventional Results available

ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer

NCT03733119
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Akt/ERK Inhibitor ONC201, Methionine-Restricted Diet
Drug · Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 74 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Nov 11, 2026, 5:49 AM EST
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

NCT04768881
View directory record Official record
Conditions
Locally Advanced Unresectable or Metastatic Melanoma
Interventions
Selinexor, Pembrolizumab
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
13
States / cities
Los Angeles, California • Pasadena, California • Plantation, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Nov 11, 2026, 5:49 AM EST
Completed Phase 1 Interventional

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

NCT04109456
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
IN10018, Cobimetinib, Atezolizumab
Drug · Biological
Lead sponsor
InxMed (Shanghai) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Miami, Florida • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Nov 11, 2026, 5:49 AM EST
Completed Phase 1 Interventional

Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery

NCT02120222
View directory record Official record
Conditions
Recurrent Melanoma
Interventions
selinexor, Correlative studies
Drug · Other
Lead sponsor
Kari Kendra
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Nov 11, 2026, 5:49 AM EST
Completed Phase 2 Interventional Results available

Raltegravir Therapy for Women With HIV and Fat Accumulation

NCT00656175
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
raltegravir
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Nov 11, 2026, 5:49 AM EST
Active, not recruiting Not applicable Interventional

RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy

NCT03524430
View directory record Official record
Conditions
Breast Neoplasm Female
Interventions
Core needle biopsy
Procedure
Lead sponsor
Rna Diagnostics Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
801 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Nov 11, 2026, 5:49 AM EST
Withdrawn Not applicable Interventional

Early Carbon Dioxide Laser Therapy for Alleviation of Incisional Scar Burden

NCT03306628
View directory record Official record
Conditions
Skin Scarring
Interventions
CO2 Laser Administration
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 80 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Nov 11, 2026, 5:49 AM EST
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

NCT06624228
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab, Risankizumab, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
34
States / cities
Gilbert, Arizona • Glendale, Arizona • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Nov 11, 2026, 5:49 AM EST
Active, not recruiting Phase 2 Interventional

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

NCT03650894
View directory record Official record
Conditions
Breast Neoplasm Female, Breast Cancer, Breast Carcinoma, Breast Tumor
Interventions
Nivolumab, Ipilimumab, Bicalutamide
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 11, 2026, 5:49 AM EST
Terminated No phase listed Observational Results available

Gene Expression in Tumor Tissue From Women Undergoing Surgery for Breast Cancer or Core Biopsy of the Breast

NCT00898937
View directory record Official record
Conditions
Breast Cancer
Interventions
microarray analysis, breast biopsy
Genetic · Procedure
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Nov 11, 2026, 5:49 AM EST
Terminated Phase 1Phase 2 Interventional Results available

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

NCT02711137
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Nov 11, 2026, 5:49 AM EST
Recruiting Phase 3 Interventional

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

NCT06072612
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
Interventions
SV-BR-1-GM, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
Biological · Drug
Lead sponsor
BriaCell Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
79
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Nov 11, 2026, 5:49 AM EST
Recruiting Phase 2 Interventional

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

NCT07102381
View directory record Official record
Conditions
HER2-positive Breast Cancer, Breast Cancer
Interventions
Zanidatamab, Paclitaxel, Docetaxel, Carboplatin, Trastuzumab, Pertuzumab
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
34
States / cities
Long Beach, California • Los Alamitos, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 11, 2026, 5:49 AM EST
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea

NCT00823901
View directory record Official record
Conditions
Rosacea
Interventions
Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel, Placebo gel
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Stanford, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Nov 11, 2026, 5:49 AM EST
Recruiting Not applicable Interventional

Clinical Trial Evaluating an Amnion Membrane Allograft for Use in the Management of Non- Healing Diabetic Foot Ulcers Versus Standard Of Care

NCT06767501
View directory record Official record
Conditions
Diabetic Foot Ulcers (DFUs)
Interventions
E-GRAFT ™, FIBRACOL™
Other · Device
Lead sponsor
Skye Biologics Holdings, LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Nov 11, 2026, 5:49 AM EST